Oncology & Cancer
FDA approves augtyro for NTRK-positive advanced solid tumors
The U.S. Food and Drug Administration has approved Augtyro (repotrectinib), a next-generation tyrosine kinase inhibitor (TKI), for the treatment of patients with neurotrophic tyrosine receptor kinase (NTRK)-positive locally ...
Jun 21, 2024
0
0